Therapeutics News

The balance between investigational new drug access and protection of patients from therapies without established safety the FDA built during the past 20 years could be compromised by the new Right to Try law, a new study in JAMA Network Open suggests.

Quest Products has announced that its Blue Guard Eye Health supplement is now available in the eye care section at all Target locations across the country, as well as online at Target.com.

NEPTUNE, N.J. – Brian Hall, OD, prioritized oral antibiotics used in the systemic management of ocular disorders here at the New Jersey Academy of Optometry continuing education meeting. Penicillins are the most commonly prescribed and are, “very effective for infections around the ocular adnexa and ocular tissue,” Hall said.

Researchers reported at the Association for Research in Vision and Ophthalmology meeting that a new eye drop containing perfluorohexyloctane improved tear film and lipid layer thickness in patients with mild to moderate dry eye disease.

OcuMedic Inc. announced that it expects to begin clinical studies for its drug-eluting contact lens technology this year.

Teva Canada Ltd. announced the launch of Teva-Cyclosporine ophthalmic emulsion, 0.05%, a twice-daily eye drop used in the treatment of dry eye.

The Dry Eye Workshop report in 2017 emphasized inflammation in dry eye disease and helped shift our traditional approach from treating the disease primarily with lubrication.

Switching to preservative-free tafluprost for long-term glaucoma therapy led to improved tear film thickness, breakup time and Dry Eye-Related Quality-of-Life Score, according to a recent study.

Patient safety always comes first, but access to unapproved drugs is sometimes vital to saving lives, or at least eyes.

The Dry Eye Assessment and Management Study Research Group concluded that patients with dry eye who received 3,000 mg of fish-derived n-3 fatty acids for 12 months had no significantly better outcomes than patients who received an olive oil placebo.